Skip to main content
. 2017 Oct 18;12(10):e0186012. doi: 10.1371/journal.pone.0186012

Fig 2. Both low and high doses of risedronate inhibit osteoclast activity resulting from estrogen depletion, but the effect is positively associated with the drug doses.

Fig 2

A) TRAP-positive mononuclear cells on the bone surface (arrow); B) TRAP-positive multinuclear osteoclast on the bone surface (arrow); C&D) Comparison of TRAP positive osteoclast surface (TRAP+OcS/BS)(C) and TRAP positive osteoclast number (TRAP+Oc.N/BS)(D), respectively, among SHAM, OVX, OVX-LR and OVX-HR groups. *p < 0.05 versus OVX group; #p < 0.05 versus SHAM group; +p < 0.05 versus OVX-LR group. Numerical data are presented in supporting information (S2 Table).